1/13
10:48 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
1/10
08:41 pm
arwr
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]
Low
Report
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]
1/9
12:27 pm
arwr
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]
Low
Report
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]
1/8
06:17 am
arwr
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]
1/7
11:05 pm
arwr
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Low
Report
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
1/7
07:12 pm
arwr
ARWR: Encouraging Early Data for Obesity Programs… [Yahoo! Finance]
Low
Report
ARWR: Encouraging Early Data for Obesity Programs… [Yahoo! Finance]
1/7
01:18 pm
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $50.00 to $85.00. They now have a "neutral" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $50.00 to $85.00. They now have a "neutral" rating on the stock.
1/7
10:35 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $48.00 to $81.00. They now have an "equal weight" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $48.00 to $81.00. They now have an "equal weight" rating on the stock.
1/7
08:33 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Chardan Capital from $60.00 to $80.00. They now have a "buy" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Chardan Capital from $60.00 to $80.00. They now have a "buy" rating on the stock.
1/7
07:41 am
arwr
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China [Yahoo! Finance]
1/7
07:30 am
arwr
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Medium
Report
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
1/6
06:14 pm
arwr
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Medium
Report
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
1/6
03:10 pm
arwr
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update [Seeking Alpha]
Low
Report
Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update [Seeking Alpha]
1/6
07:30 am
arwr
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
High
Report
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
1/6
05:20 am
arwr
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS [Yahoo! Finance]
High
Report
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS [Yahoo! Finance]
1/5
10:00 am
arwr
Arrowhead Pharmaceuticals Says Health Canada Issues 'Notice of Compliance' for Redemplo for Triglyceride Disorder [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Says Health Canada Issues 'Notice of Compliance' for Redemplo for Triglyceride Disorder [Yahoo! Finance]
1/5
07:37 am
arwr
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) [Yahoo! Finance]
1/5
07:30 am
arwr
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Medium
Report
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
12/23
07:30 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
12/19
09:23 am
arwr
Non-Viral Gene Delivery Technologies Market Size to Hit USD 9.57 Billion by 2033, Growing at a CAGR of 12.55% - SNS Insider [Yahoo! Finance]
Low
Report
Non-Viral Gene Delivery Technologies Market Size to Hit USD 9.57 Billion by 2033, Growing at a CAGR of 12.55% - SNS Insider [Yahoo! Finance]
12/17
08:05 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an "overweight" rating on the stock.
12/15
04:30 pm
arwr
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12/11
10:44 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an "outperform" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an "outperform" rating on the stock.
12/9
01:15 pm
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a "buy" rating on the stock.
12/8
07:30 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
High
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies